What is Theralase Technologies Inc.?
, a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally.
TLTFF · Verdict
Moderate reward · elevated risk
TLTFF's standout is volatility; cash flow and profitability weigh on the picture.
Based on 88% data coverage
TLTFF · Verdict
Top decile vs peers
-324% free-cash-flow margin
-412% net margin · -269% ROE
Model-based scoring. For information only — not financial advice.
, a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. The company is listed on the OTCQB in USA, operating in the Healthcare sector, with a market capitalisation of 55.63M.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.